RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY

被引：17
|
作者：
Finch, Rebecca [1 ]
Sostelly, Alexandre [2 ]
Sue-Ling, Kim [3 ]
Blaeuer, Angela [2 ]
Duchateau-Nguyen, Guillemette [2 ]
Ukarma, Lidia [2 ]
Petry, Claire [2 ]
Ravva, Patanjali [2 ]
Villiger, Peter [4 ]
Junker, Uwe [2 ]
机构：
[1] Roche Prod Ltd, Welwyn Garden City, England
[2] Roche Innovat Ctr Basel, Basel, Switzerland
[3] Roche Innovat Ctr New York, New York, NY USA
[4] Inselspital Bern, Bern, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.3028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0224
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [1] Dynamic contrast enhanced MRI of the wrist demonstrates early response to anti-TNFalpha therapy in rheumatoid arthritis.
    Hodgson, Richard
    Barnes, Theresa
    Connolly, Sylvia
    Eyes, Brian
    Campbell, Robert
    Moots, Robert
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S134 - S135
  • [2] Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
    Genovese, Mark C.
    Fleischmann, Roy M.
    Greenwald, Maria
    Satterwhite, Julie
    Veenhuizen, Melissa
    Xie, Li
    Berclaz, Pierre-Yves
    Myers, Stephen
    Benichou, Olivier
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (09) : 1461 - 1468
  • [3] Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study
    Taylor, Peter C.
    Schett, Georg
    Huizinga, Tom W. J.
    Wang, Qingmin
    Ibrahim, Fowzia
    Zhou, Bei
    Liva, Sophia G.
    Shaik, Jafar Sadik B.
    Xiong, Yuan
    Leu, Jocelyn H.
    Panchakshari, Rohit A.
    Loza, Matthew J.
    Ma, Keying
    Dhatt, Harman
    Rojo Cella, Ricardo
    Karyekar, Chetan S.
    Cuff, Carolyn A.
    Gao, Sheng
    Fei, Kaiyin
    RMD OPEN, 2024, 10 (02):
  • [4] IMPACT OF ANTI-IL-6 MONOCLONAL ANTIBODY, CLAZAKIZUMAB, ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE IN A PHASE IIB STUDY
    Alemao, E.
    Joo, S.
    Banerjee, S.
    Emery, P.
    Weinblatt, M.
    L'ltalien, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 947 - 947
  • [5] Aglycosyl anti-CD3 monoclonal antibody therapy in rheumatoid arthritis - Results of a pilot safety study
    Lawson, CA
    Griffiths, B
    Ponchel, F
    Hale, G
    Waldmann, H
    Isaacs, JD
    RHEUMATOLOGY, 2005, 44 : I24 - I24
  • [6] eLetter: Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors by M Genovese
    Triantafyllou, Areti
    Pyrpasopoulou, Athina
    Anyfanti, Panagiota
    Balaska, Ekaterini
    Aslanidis, Spyros
    Douma, Stella
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (05) : E7 - E7
  • [7] HUMAN ANTI-MOUSE ANTIBODY-RESPONSE INDUCED BY ANTI-CD4 MONOCLONAL-ANTIBODY THERAPY IN PATIENTS WITH RHEUMATOID-ARTHRITIS
    HORNEFF, G
    WINKLER, T
    KALDEN, JR
    EMMRICH, F
    BURMESTER, GR
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1991, 59 (01): : 89 - 103
  • [8] NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-α monoclonal antibody therapy
    D. Kalden-Nemeth
    J. Grebmeier
    F. Wolf
    C. Antoni
    B. Manger
    J. R. Kalden
    Rheumatology International, 1997, 16 : 249 - 255
  • [9] Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study
    Monnet, Emmanuel
    Choy, Ernest H.
    McInnes, Iain
    Kobakhidze, Tamta
    de Graaf, Kathy
    Jacqmin, Philippe
    Lapeyre, Genevieve
    de Min, Cristina
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (03) : 316 - 323
  • [10] The safety of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF therapy: Results from the arrive trial
    Schiff, M.
    Pritchard, C.
    Teng, J.
    Bahrt, K.
    Genovese, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 89 - 89
12345